
Bio-Techne Corporation
TECHNASDAQHealthcareBiotechnology
最新資料
US$72.34
+US$0.04 · +0.06%
TECH公司概覽
盤中時間採用ET。市場資料可能有所延遲。
GoAI 研究快照
簡明呈現最新可用的模型資訊。
GoAI評分
Hold
Wait — insufficient conviction to act
估值
48
Fair Value
動能
62
Gaining
情緒
58
Mixed
風險韌性
59
Elevated Risk
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
人工智慧產生的上下文僅供參考,並非投資建議。
公司概況
公司網站Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- 產業
- Biotechnology
- 部門
- Healthcare
- 總部
- US
- 執行長
- Kim Kelderman
- 上市以來
- 1989年2月9日
- 僱員
- 3,000
市場位置
- 成交量
- 395.8萬
- 0.92× 平均值
- 平均成交量
- 428.18萬
- 日均成交量
- 市值
- 113.23億 USD
- 貝塔
- 1.28
- 市場參考 1
財務數據
財務快照
最近十二個月財務健康
- 奧特曼 Z 分數
- 15.25
- 皮奧特羅斯基 F 分數
- 8 共 9 個
財報歷史與展望
- 最新財年每股收益
- 1.16
- 2026會計年度 · 年增+152.17%
- 最新財年收入
- 12.15億 USD
- 2026會計年度 · 年增-0.38%
- 下一財年每股收益共識
- 2.06
- 2027會計年度 · 3位分析師
- 下一財年營收共識
- 12.66億 USD
- 2027會計年度 · 10位分析師
年度每股收益趨勢
已公布業績及可用的市場共識預估。
年度營收趨勢
已公布業績及可用的市場共識預估。
TECH同業公司
繼續GoAI的研究
在 GoAI 中研究TECHresearch.disclaimer





